{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:01:25Z","timestamp":1787504485887,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bmcl.2023.129489","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:30:50Z","timestamp":1695763850000},"page":"129489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-1841","authenticated-orcid":false,"given":"Arun K.","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie E.C.","family":"Imhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kovela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-3397","authenticated-orcid":false,"given":"Shin-ichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyo","family":"Higashi-Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Mesecar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129489_b0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129489_b0010","article-title":"Managing uncertainty in the covid-19 era","volume":"370","author":"Rutter","year":"2020","journal-title":"Br Med J"},{"key":"10.1016\/j.bmcl.2023.129489_b0015","unstructured":"World Health Organization. Coronavirus Disease (COVID-19) Situation Report. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (accessed on)."},{"key":"10.1016\/j.bmcl.2023.129489_b0020","unstructured":"Coronavirus COVID-19 (2019-nCoV). https:\/\/gisanddata.maps.arcgis.com\/apps\/dashboards\/bda7594740fd40299423467b48e9ecf6."},{"key":"10.1016\/j.bmcl.2023.129489_b0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(22)00100-3","article-title":"COVID-19 will continue but the end of the pandemic is near","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129489_b0030","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/jama.2022.9655","article-title":"COVID-19 in 2022-the beginning of the end or the end of the beginning?","volume":"327","author":"Del Rio","year":"2022","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bmcl.2023.129489_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 vaccine: a comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res"},{"key":"10.1016\/j.bmcl.2023.129489_b0040","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129489_b0045","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129489_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102779","article-title":"Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies","volume":"126","author":"Kannan","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bmcl.2023.129489_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2023.129489_b0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/cid\/ciab456","article-title":"Novel canine coronavirus isolated from a hospitalized patient with pneumonia in East Malaysia","volume":"74","author":"Vlasova","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2023.129489_b0065","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2004.11.038","article-title":"Programmed ribosomal frameshifting in decoding the SARS-CoV genome","volume":"332","author":"Baranov","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.bmcl.2023.129489_b0070","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/0022-1317-81-4-853","article-title":"Virus-encoded proteinases and proteolytic processing in the Nidovirales","volume":"81","author":"Ziebuhr","year":"2000","journal-title":"J Gen. Virol"},{"key":"10.1016\/j.bmcl.2023.129489_b0075","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2023.129489_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200440","article-title":"Recent drug development and medicinal chemistry approaches for the treatment of SARS-CoV-2 infection and COVID-19","volume":"17","author":"Ghosh","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2023.129489_b0085","first-page":"183","article-title":"Progress in anti-SARS coronavirus chemistry, biology and chemotherapy","volume":"41","author":"Ghosh","year":"2007","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/j.bmcl.2023.129489_b0090","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129489_b0095","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2023.129489_b0100","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2023.129489_b0105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2023.129489_b0110","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2023.129489_b0115","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/M22-0281","article-title":"Prescribing nirmatrelvir-ritonavir: how to recognize and manage drug-drug interactions","volume":"175","author":"Marzolini","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmcl.2023.129489_b0120","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmcl.2023.129489_b0125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2023.129489_b0130","article-title":"Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.bmcl.2023.129489_b0135","article-title":"Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study","volume":"33","author":"Liu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129489_b0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmcl.2023.129489_b0145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129489_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004113","article-title":"Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease","volume":"10","author":"Ratia","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmcl.2023.129489_b0155","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/ijms17050678","article-title":"SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2023.129489_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.876212","article-title":"Inhibitors of SARS-CoV-2 PLpro","volume":"10","author":"Calleja","year":"2022","journal-title":"Frontiers in Chem."},{"key":"10.1016\/j.bmcl.2023.129489_b0165","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.bmcl.2023.129489_b0170","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2023.129489_b0175","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm900611t","article-title":"Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease","volume":"52","author":"Ghosh","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129489_b0180","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein\u2212 ligand X-ray structure and biological evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129489_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.822785","article-title":"Potential inhibitors targeting papain-like protease of SARS-CoV-2: two birds with one stone","volume":"10","author":"Jiang","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.bmcl.2023.129489_b0190","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2023.129489_b0195","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J"},{"key":"10.1016\/j.bmcl.2023.129489_b0200","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129489_b0205","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acsinfecdis.2c00091","article-title":"Pyronaridine protects against SARS-CoV-2 infection in mouse","volume":"8","author":"Puhl","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2023.129489_b0210","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s13238-022-00909-3","article-title":"Targeting papain-like protease for broad-spectrum coronavirus inhibition","volume":"13","author":"Yuan","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.bmcl.2023.129489_b0215","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2023.129489_b0220","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2023.129489_b0225","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharmaceut Sin B"},{"key":"10.1016\/j.bmcl.2023.129489_b0230","unstructured":"Please see the supporting information section for compound characterization data & assay protocols."},{"key":"10.1016\/j.bmcl.2023.129489_b0235","unstructured":"We conducted modeling studies in the 3CLpro active site using Maestro Schr\u00f6dinger Suite 2018.48 The protein was minimized using Protein Preparation Wizard and the inhibitor was optimized using Lig Prep tool from Maestro 11.8.49."},{"key":"10.1016\/j.bmcl.2023.129489_b0240","unstructured":"Maestro, version 11.8. Schr\u00f6dinger, LLC, New York. https:\/\/www.schrodinger.com\/maestro."},{"key":"10.1016\/j.bmcl.2023.129489_b0245","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Madhavi","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmcl.2023.129489_b0250","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-021-20900-6","article-title":"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"12","author":"Hattori","year":"2021","journal-title":"Nat Commun"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23003670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23003670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:48:22Z","timestamp":1760773702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23003670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":50,"alternative-id":["S0960894X23003670"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129489","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129489"}}